We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. 89bio, Inc. is one of them. 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company, focuses on developing therapies for liver and cardiometabolic diseases, particularly metabolic dysfunction-associated steatohepatitis (MASH). Its lead candidate, pegozafermin, is a long-acting FGF21 analog designed to treat moderate to severe MASH, including advanced fibrosis, as well as related metabolic disorders. In ...

We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. Verona Pharma plc is one of them. Verona Pharma plc (NASDAQ:VRNA) is a biopharmaceutical company developing therapies for respiratory diseases. Its lead product, Ohtuvayre (ensifentrine), is a first-in-class inhaled dual inhibitor of PDE3 and PDE4 for maintenance treatment of chronic obstructive pulmonary disease (COPD). Combining bronchodilator and anti-inflammatory effects, Ohtuvayre received FDA approval in June 2 ...

We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. Insmed Incorporated is one of them. Insmed Incorporated (NASDAQ:INSM) tops our list for being one of the best performing stocks. It is a biopharmaceutical company focused on rare diseases, with a portfolio targeting serious conditions with unmet medical needs. Its flagship product, ARIKAYCE® (amikacin liposome inhalation suspension), addresses lung infections and has shown strong market growth. Recently, INSM gained ...

Rapport Therapeutics, Inc. (NASDAQ:RAPP) is among the best fast money stocks to buy now. Analysts at JMP Securities have reaffirmed their ‘Market Outperform’ rating on Rapport Therapeutics, Inc. (NASDAQ:RAPP) with a price target of $77, implying a potential surge of about 174%. This announcement follows the publication of “stellar results” from the Phase 2a trial for RAP-219 in refractory focal epilepsy. Keeping in view the year-to-date returns posted by Rapport Therapeutics, Inc. (NASDAQ:RAPP), the compa ...

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is among the best fast money stocks to buy now. During the first quarter, Goldman Sachs Group Inc. expanded its holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 93.6%. Following the purchase of 358,412 shares, the leading bank now owns 741,329 shares of the company’s stock, translating to an investment of $2,787,000 and an ownership of nearly 1.08%. Oppenheimer is among the many research firms bullish on Olema Pharmaceuticals, Inc. (NASDAQ:OLMA). After the ...

Annexon, Inc. (NASDAQ:ANNX) is among the best fast money stocks to buy now. During the first quarter, Nuveen LLC acquired a new position in Annexon, Inc. (NASDAQ:ANNX) through the purchase of 23,491 shares of the company’s stock. According to a recent disclosure with the SEC, the global asset firm now owns 0.14% of the company, translating to an investment of approximately $666,000. What makes Annexon, Inc. (NASDAQ:ANNX) truly exciting is its one-of-a-kind programs. If we consider the Guillain-Barré syndr ...

Company announcement – No. 21 / 2025 Total number of shares and voting rights in Zealand Pharma as of September 30, 2025 Copenhagen, Denmark, September 30, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of ...

MBX Biosciences (NasdaqGS:MBX) Conference September 30, 2025 10:00 AM ET Company ParticipantsSalomon Azoulay - CMOKent Hawryluk - CEOModeratorHi, good morning. It's our pleasure to have MBX Biosciences with us today, who is best known for its Precision Endocrine Peptide Canvuparatide for hypoparathyroidism, but they've also leveraged their program to various conditions in the cardiometabolic space. Specifically, they have MBX 1416, a GLP-1 antagonist for post-bariatric hypoglycemia, and also MBX 4291, which ...

PHILADELPHIA, Sept. 30, 2025 (GLOBE NEWSWIRE) --  Berger Montague PC is investigating potential securities fraud claims on behalf of investors of Altimmune, Inc. (NASDAQ: ALT) (“Altimmune” or the “Company”) following the filing of a securities class action lawsuit filed on behalf of investors who purchased or otherwise acquired Altimmune securities between August 10, 2023 through June 25, 2025 (the “Class Period”). Investor Deadline: Investors who purchased or acquired Altimmune securities during the Class ...

This story was originally published on Manufacturing Dive. To receive daily news and insights, subscribe to our free daily Manufacturing Dive newsletter. Biopharmaceutical giant Amgen said it plans to invest $650 million to increase drug production at its Juncos, Puerto Rico, facility, as part of a larger effort to expand its U.S. manufacturing network. The investment is expected to create nearly 750 jobs, including in construction and highly-skilled manufacturing roles. It also will support advanced techn ...